Letrozole 2,5 mg/tab 30 pills |

About Letrozole | HilmaBiocare

Letrozole - Hilma Biocare

Letrozole is a prescription, non-steroidal aromatase inhibitor (AI) that reduces estrogen production by inhibiting the aromatase enzyme responsible for converting androgens into estrogens. It has established medical use, primarily in hormone receptor–positive breast cancer in postmenopausal patients under professional supervision.

General Overview

Class: Aromatase inhibitor (AI), non-steroidal
Structure: Letrozole (non-steroidal aromatase inhibitor)
Context of use: Prescription medical use under professional supervision; estrogen suppression in clinically appropriate contexts

Potentially Observed Effects
(based on pharmacological action and clinical use)

Marked reduction of circulating estradiol levels
Decreased estrogen-related activity in tissues where suppression is clinically relevant
Possible reduction of estrogen-related fluid retention in some individuals (individual response varies)

Safety Information

Letrozole may be associated with side effects and clinically important risks. Reported adverse effects can include fatigue, headache, dizziness, nausea, hot flashes, sleep disturbances, and musculoskeletal discomfort (e.g., joint pain). Long-term estrogen suppression may negatively affect bone mineral density and can adversely influence lipid profile in susceptible individuals. Elevations in liver enzymes can occur but are not among the most common reactions. Individual responses vary, and use should be guided by a qualified medical professional with appropriate monitoring when indicated.

Disclaimer: This text is provided for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Always comply with the laws of your country and use prescription medicines only under qualified medical supervision.